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Abstract
Background:	The	International	Federation	of	Gynecology	and	Obstetrics	(FIGO)	sys-
tems	for	nomenclature	of	symptoms	of	normal	and	abnormal	uterine	bleeding	(AUB)	
in	the	reproductive	years	(FIGO	AUB	System	1)	and	for	classification	of	causes	of	AUB	
(FIGO	AUB	System	2;	PALM-	COEIN)	were	first	published	together	in	2011.	The	pur-
pose	was	 to	harmonize	 the	definitions	of	normal	and	abnormal	bleeding	symptoms	
and	to	classify	and	subclassify	underlying	potential	causes	of	AUB	in	the	reproductive	
years	to	facilitate	research,	education,	and	clinical	care.	The	systems	were	designed	to	
be	flexible	and	to	be	periodically	reviewed	and	modified	as	appropriate.
Objectives:	 To	 review,	 clarify,	 and,	 where	 appropriate,	 revise	 the	 previously	
published	systems.
Methodology and outcome:	To	a	large	extent,	the	process	has	been	an	iterative	one	
involving	the	FIGO	Menstrual	Disorders	Committee,	as	well	as	a	number	of	 invited	
contributions	from	epidemiologists,	gynecologists,	and	other	experts	in	the	field	from	
around	the	world	between	2012	and	2017.	Face-	to-	face	meetings	have	been	held	in	
Rome,	Vancouver,	and	Singapore,	and	have	been	augmented	by	a	number	of	telecon-
ferences	and	other	communications	designed	to	evaluate	various	aspects	of	the	sys-
tems.	Where	substantial	change	was	considered,	anonymous	voting,	in	some	instances	
using	a	modified	RAND	Delphi	technique,	was	utilized.
K E Y W O R D S
Abnormal	uterine	bleeding;	Adenomyosis;	Anovulatory	bleeding;	Arteriovenous	malformation;	
Coagulopathy;	Endometrial	hyperplasia;	Endometrial	polyp;	FIGO;	Heavy	menstrual	bleeding;	
Heavy	uterine	bleeding;	Intermenstrual	bleeding;	Irregular	menstrual	bleeding;	Irregular	uterine	
bleeding;	Isthmocele;	Leiomyoma;	Menorrhagia;	Metrorrhagia;	PALM-COEIN
1  | INTRODUCTION
The	worldwide	impact	of	abnormal	uterine	bleeding	(AUB)	in	the	repro-
ductive	years	is	substantial,	with	a	prevalence	of	approximately	3%–30%	
among	reproductive	aged	women.	The	reasons	for	the	wide	spectrum	
of	estimates	are	unclear	but	vary	with	age,	being	higher	in	adolescents	
and	 in	the	fifth	decade	of	 life,	and	varying	somewhat	with	country	of	
origin.1–9	Approximately	one	third	of	women	are	affected	at	some	time	
in	their	life.3,6	Many	of	the	published	studies	are	restricted	to	estimates	
of	the	prevalence	of	the	symptoms	of	heavy	menstrual	bleeding	(HMB);	
when	other	symptoms,	particularly	those	of	irregular	and	intermenstrual	
bleeding	are	included,	the	prevalence	rises	to	35%	or	higher.9
Available	evidence	suggests	that	as	many	as	half	of	affected	women	
do	 not	 seek	medical	 care,	 even	 if	 they	 have	 access	 to	 a	 healthcare	
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provider,4,5,8	a	circumstance	that	may	explain	the	variation	in	reported	
prevalence.	The	manifestations	vary	from	modest	to	severe	disruption	
of	work	productivity	and	quality	of	 life,10,11	and	 increasing	maternal	
morbidity	and	mortality	for	pregnant	women	with	pre-	existing	AUB-	
related	anemia.12,13
In	2011,	recognizing	the	international	need	created	by	the	impact	
of	 AUB,	 the	 International	 Federation	 of	 Gynecology	 and	 Obstetrics	
(FIGO),	published	a	pair	of	systems	and	a	set	of	clinical	recommenda-
tions	with	the	aim	of	informing	and	aiding	clinicians	and	investigators	in	
the	design	and	interpretation	of	investigations	into	AUB	in	the	repro-
ductive	years,	as	well	as	the	provision	of	evidence-	based	clinical	care.14
The	present	manuscript	was	designed	to	provide	a	detailed	update	
on	the	FIGO	recommendations	concerning	 terminologies,	definitions,	
and	underlying	causes	of	AUB	in	the	reproductive	years.	Revised	ter-
minologies	 and	 definitions	 of	 normal	menstrual	 parameters,	 and	 the	
symptoms	of	AUB	were	initially	published	in	2007,15,16	while	the	sem-
inal	 2011	 publication14	 presented	 both	 systems—Terminology	 and	
Definitions	(FIGO-	AUB	System	1)	and	Classification	of	Causes	of	AUB	in	
the	Reproductive	Years,	the	PALM-	COEIN	system	(FIGO-	AUB	System	
2).	From	the	beginning,	it	was	determined	that	these	recommendations	
should	 be	flexible	 and	 subject	 to	ongoing	 regular	 review	 to	 incorpo-
rate	 results	of	new	research	and	analysis.	These	review	periods	were	
intended	to	broadly	coincide	with	the	triennial	FIGO	World	Congresses.
The	first	key	recommendations,	published	simultaneously	in	2007	
in	 Fertility	 Sterility	 and	 Human	 Reproduction,15,16 recommended a 
substantial	 revision	of	existing	 terminologies	and	definitions	 for	 the	
description	of	AUB	 features	and,	by	doing	 so,	 redefined	 the	normal	
parameters	of	menstrual	bleeding.	Recommended	was	the	abolition	of	
terms	(largely	of	Latin	and	Greek	origin)	such	as	menorrhagia,	metror-
rhagia,	and	dysfunctional	uterine	bleeding,	which	were	poorly	defined,	
used	 internationally	 in	 a	 disparate	 manner,	 and	 had	 no	 consistent	
meaning	for	the	general	and	academic	communities.15–17
The	 second	 key	 publication14	 presented	 a	 novel	 and	 pragmatic	
approach	 to	 classification	 of	 the	 underlying	 causes	 of	AUB	 in	 non-	
pregnant	 women.	 No	 such	 systematic	 classification	 of	 underlying	
causes	 existed	 at	 that	 time.	 This	 2011	 manuscript	 introduced	 the	
PALM-	COEIN	 classification	 based	 on	 clinical-	 and	 imaging-	based	
stratification	 of	 causes	 into	 “structural”	 pathologies	 that	 can	 be	
“imaged”	 and/or	 defined	 histopathologically	 (Polyps,	 Adenomyosis,	
Leiomyomas	 and	 Malignancy	 or	 atypical	 endometrial	 hyperplasia;	
PALM).	 The	 remaining	 causes	were	 categorized	 as	 “non-	structural”,	
in	that	they	cannot	be	 imaged,	but	clinical	assessment	with	detailed	
history	 and	 appropriate	physical	 examination,	 sometimes	 supported	
by	laboratory	testing,	can	largely	imply	or	make	a	diagnosis	of	cause	
(Coagulopathies,	Ovulatory	disorders,	primary	Endometrial	disorders,	
Iatrogenic	and	Not	otherwise	classified;	COEIN).
It	rapidly	became	clear	that	each	of	these	individual	causes	could	
require	division	into	subclassifications	of	cause	and	phenotype	to	opti-
mize	clinical	management	and	support	the	broad	spectrum	of	research	
needed.	The	subclassification	of	leiomyomas	was	an	obvious	starting	
point.14	Three	key	publications14–17	formed	the	foundation	of	a	sim-
ple,	flexible,	and	educationally	sound	pair	of	descriptive	systems	that	
were	designed	to	provide	a	quick	initial	clinical	direction	of	diagnosis	
and	management,	but	also	to	be	flexible	enough	to	provide	effective	
linkages	with	laboratory	and	research	aspects.
The	present	report	updates	the	FIGO	recommendations	for	both	
FIGO-	AUB	Systems	1	and	2,	including	clarifications	on	terminologies	
and	definitions,	as	well	as	modifications	in	the	PALM-	COEIN	system	
that	include	reassignment	of	some	entities,	and	guidance	for	subclas-
sification	of	 leiomyomas,	much	of	which	has	been	preliminarily	pub-
lished.18–20	These	changes	represent	structured	deliberative	processes	
that	 include	use	of	a	modified	RAND	Delphi	process	applied	 to	 the	
attendees	of	a	series	of	FIGO	Menstrual	Disorders	Committee	(MDC)	
sponsored	 expert	 meetings.	 To	 allow	 this	 report	 to	 function	 inde-
pendently,	and	to	provide	context,	there	exists	substantial	but	neces-
sary	overlap	with	the	original	publication,14	and	with	other	subsequent	
and	related	publications	produced	by	the	MDC	since	2011.18–24
The	FIGO	MDC	is	currently	working	on	subclassification	systems	for	
adenomyosis	and	endometrial	polyps.	The	adenomyosis	 subclassifica-
tion	system	is	the	most	advanced	and	will	be	published	soon	in	prelimi-
nary	form	with	planned	validation	studies	to	follow.	The	polyp	system	is	
being	developed	but	a	release	date	has	not	yet	been	determined.	There	
is	consideration	for	subclassification	systems	for	AUB-	C,	-	O,	-	E,	and	–I,	
but	these	initiatives	are	still	in	the	very	early	stages	of	development.
It	is	important	that	clinicians	recognize	that	these	FIGO	systems	relate	
solely	to	assessment	and	management	of	nongestational	AUB.	There	are	
other	causes	of	genital	tract	bleeding	and	urinary	tract	or	gastrointestinal	
bleeding	that	do	not	come	from	the	uterus.	These	can	usually	be	identi-
fied	by	an	appropriate	case	history	and	physical	examination.
2  | ACUTE VERSUS CHRONIC 
NONGESTATIONAL AUB IN THE 
REPRODUCTIVE YEARS
In	 the	 original	 system,14	 FIGO	 introduced	 the	 concept	 of	 nonges-
tational	acute	AUB	 in	 the	 reproductive	years,	distinguishing	 it	 from	
chronic	 AUB—an	 approach	 endorsed	 by	 the	 American	 College	
of	 Obstetricians	 and	 Gynecologists.25	 These	 definitions	 remain	
unchanged	for	2018.	Chronic	nongestational	AUB	in	the	reproductive	
years	is	defined	as	bleeding	from	the	uterine	corpus	that	is	abnormal	
in	duration,	volume,	frequency,	and/or	regularity,	and	has	been	pre-
sent	for	the	majority	of	the	preceding	6	months.	Acute	AUB,	on	the	
other	 hand,	 is	 defined	 as	 an	 episode	of	 heavy	bleeding	 that,	 in	 the	
opinion	of	the	clinician,	is	of	sufficient	quantity	to	require	immediate	
intervention	to	minimize	or	prevent	further	blood	loss.	Acute	heavy	
menstrual	 bleeding	 may	 present	 in	 the	 context	 of	 existing	 chronic	
AUB	or	can	occur	in	the	absence	of	such	a	background	history.
3  | FIGO- AUB SYSTEM 1
3.1 | Revision of terminologies and definitions of 
symptoms of abnormal uterine bleeding
The	 revised	 FIGO-	AUB	 System	1	 is	 seen	 in	 Figure	1,	with	 changes	
summarized	 in	Table	1.	As	determined	by	 the	multinational	process	
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described	 in	 the	original	publications,14–16	 terms	such	as	menorrha-
gia,	metrorrhagia,	 oligomenorrhea,	 and	dysfunctional	 uterine	 bleed-
ing	have	been	abandoned.	There	is	acknowledgement	of	the	specific	
changes	 in	 menstrual	 bleeding	 patterns	 that	 may	 be	 encountered	
at	 each	 end	 of	 the	 reproductive	 spectrum	 (i.e.	 in	 adolescence	 or	
the	peri-	menopause).26
Preparation	 of	 the	 present	 2018	 recommendations	 is	 the	 result	
of	sequential	reviews	of	the	FIGO-	AUB	System	1	initially	proposed	in	
2007	and	2009,	and	underwent	slight	modification	for	2011.	The	cur-
rent	revisions	represent	deliberations	in	meetings	held	in	2012,	2015,	
and	2017.	These	reviews	have	included	comment,	detailed	question-
ing,	and	recommendations	from	many	clinicians	from	around	the	world	
but	have	only	resulted	in	minor	changes	and	refinement	of	definitions	
from	the	original	system.
In	this	revision	of	FIGO	AUB	System	1,	the	definition	of	regular-
ity	has	been	changed	from	one	where	the	shortest	to	 longest	varia-
tion	 is	up	 to	20	days,	 to	variation	of	7–9	days,	depending	upon	age	
(18–25	years	≤9	days;	26–41	years	≤7	days;	42–45	years	≤9	days).27 
For	 practical	 purposes,	 this	 normal	 variation	 in	 cycle	 length	 can	 be	
alternatively	expressed	as	±4	days.
Formally	included	is	the	term	HMB,	a	symptom	(not	a	diagnosis),	
that	has	been	defined	(in	clinical	situations)	by	the	National	Institute	
for	Health	and	Clinical	Excellence	as	“excessive	menstrual	blood	loss,	
which	 interferes	 with	 a	 woman’s	 physical,	 social,	 emotional	 and/or	
material	quality	of	life”.5,28
4  | FIGO AUB SYSTEM 2
4.1 | Revision of classification of underlying causes 
of AUB (PALM- COEIN)
Highlights	 of	 changes	 since	 the	 original	 publication	 in	 201114 are 
summarized	in	Table	2.	The	basic/core	classification	system	is	almost	
unchanged	and	is	presented	in	Figure	2.	There	remain	the	nine	main	
F IGURE  1 FIGO	AUB	System	1.	Nomenclature	and	Definitions	of	AUB	Symptoms.	For	2018,	intermenstrual	bleeding	has	been	added,	and	
there	is	now	a	practical	definition	for	irregular	menstrual	bleeding	created	by	using	the	75th	percentile,	effectively	excluding	the	occasional	long	
or	short	cycles	experienced	by	many	women.	*The	available	evidence	suggests	that,	using	these	criteria,	the	normal	range	(shortest	to	longest)	
varies	with	age:	18–25	y	of	age,	≤9	d;	26–41	y,	≤7	d;	and	for	42–45	y,	≤9	d	Harlow	et	al.,	2000.27	For	clinical	purposes,	the	definition	of	HMB	
proposed	by	the	UK	National	Institute	for	Health	and	Care	Excellence	has	been	adopted5,28	–	“Excessive	menstrual	blood	loss	which	interferes	
with	a	woman’s	physical,	social,	emotional,	and/or	material	quality	of	life”.	Abbreviations:	AUB,	abnormal	uterine	bleeding;	FIGO,	International	
Federation	of	Gynecology	and	Obstetrics;	HMB,	heavy	menstrual	bleeding.	[Correction	added	on	12	November	2018,	after	first	online	and	print	
publication:	Frequency	parameter	has	been	updated	from	‘Infrequent	(<24	days)’	to	‘Frequent	(<24	days)’	and	‘Irregular’	modified	to	‘≥8-10	days’.]
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categories,	 arranged	 according	 to	 the	 acronym	 PALM-	COEIN	 (pro-
nounced	“palm-	koin”):	Polyp;	Adenomyosis;	Leiomyoma;	Malignancy	
and	hyperplasia;	Coagulopathy;	Ovulatory	 dysfunction;	 Endometrial	
disorders;	 Iatrogenic;	 and	Not	 otherwise	 classified.	 Category	N	 has	
undergone	a	change	from	“not	yet	classified”	to	“not	otherwise	classi-
fied”	as	we	cannot	be	certain	which,	if	any,	of	these	entities	will	ulti-
mately	be	placed	in	a	unique	category.	The	components	of	the	PALM	
group	are	generally	discrete	(structural)	entities	that	can	be	evaluated	
or	measured	visually	using	some	combination	of	imaging	techniques	
and	histopathology;	 the	COEI	group	comprises	entities	that	are	not	
defined	by	 imaging	or	histopathology	(non-	structural).	By	 its	nature,	
the	“Not	otherwise	classified”	category	includes	a	spectrum	of	poten-
tial	entities	that	may	or	may	not	be	measured	or	defined	by	histopa-
thology	or	imaging	techniques.
The	system	has	been	constructed	with	the	understanding	that	a	
given	patient	may	have	one	or	more	entities	that	could	cause	or	con-
tribute	to	AUB	symptoms	and	that	structurally	definable	entities,	such	
as	adenomyosis,	leiomyomas,	and	endocervical	or	endometrial	polyps	
are	often	asymptomatic	and,	therefore,	may	not	contribute	to	the	pre-
senting	symptoms.
Since	 the	original	publication	of	 the	FIGO	AUB	systems,14	 there	
have	been	advances	in	the	diagnosis	of	adenomyosis,	although	its	rela-
tionship	 to	 reproductive	 function	and	uterine	bleeding	 is	 still	under	
investigation.	 It	has	been	demonstrated	that	two-	dimensional	trans-
vaginal	ultrasonography	has	similar	sensitivity	and	specificity	for	the	
diagnosis	 of	 adenomyosis	 when	 compared	 to	 magnetic	 resonance	
imaging	 (MRI).29,30	 There	 is	 some	 progress	 regarding	 the	 spectrum	
of	 two-	dimensional	 ultrasonography	 findings	 associated	 with	 the	
diagnosis,31,32	 but	 no	 consensus	 regarding	 how	many	 and	which	 of	
these	findings	are	necessary	before	there	is	reasonable	certainty	that	
a	diagnosis	of	adenomyosis	is	present.	The	eight	criteria	suggested	by	
the	morphological	uterus	sonographic	assessment	(MUSA)	group	are	
shown	in	Figure	3.31	The	FIGO	MDC	is	currently	working	on	an	inter-
national	 consensus	 for	 an	 imaging-	based	 adenomyosis	 classification	
system	designed	to	phenotype	the	disorder	in	a	standardized	fashion	
that	should	facilitate	research,	education,	and	clinical	care.	However,	
for	diagnosis	the	use	of	the	transvaginal	ultrasonography-	based	MUSA	
criteria31	for	the	diagnosis	of	adenomyosis	for	the	purposes	of	FIGO	
AUB	System	2	is	suggested.
The	only	subclassification	system	ratified	so	far	is	the	leiomyoma	
subclassification	system,	essentially	unchanged	since	the	initial	2011	
publication14	(Fig.	4).	The	only	subtle	difference	is	for	Type	3	myomas,	
where	contact	with	the	endometrium	is	a	feature	shared	by	other	sub-
mucous	leiomyomas	(Types	0,	1,	and	2),	whereas	intramural	location,	
without	focal	distortion	of	the	endometrial	cavity,	 is	a	characteristic	
of	Types	4	and	higher.	The	system	now	recognizes	this	area	of	over-
lap.	 It	 is	 also	 recognized	 that	 there	are	 some	difficulties	 in	 applying	
the	leiomyoma	subclassification	system	to	the	spectrum	of	 leiomyo-
mas	 that	 can	be	encountered,	especially	 in	 large	uteri	with	multiple	
leiomyomas.33	There	is	now	more	detailed	guidance	for	distinguishing	
amongst	the	leiomyoma	subtypes.
Distinguishing	between	Type	0	and	1,	and	between	Type	6	and	7	
leiomyomas	is	now	accomplished	by	comparing	the	stalk	diameter	to	
TABLE  1 Summary	of	changes	to	FIGO	System	1	(normal	and	
abnormal	uterine	bleeding).
Parameter Change
Frequency Amenorrhea	is	now	part	of	the	frequency	
category
Regularity Refined	definition	of	regularity
	Normal	variation	(shortest	to	longest)	7-9	d
	Slight	variance	depends	on	age
Duration Now	only	two	categories	for	duration
	Normal:	≤8	d
	Prolonged:	>8	d
Volume Definition	of	the	symptom	of	HMB
	NICE	definition5,28
	Bleeding	volume	sufficient	to	interfere	with	the	
woman’s	quality	of	life
Intermenstrual	
bleeding
Definition	of	the	symptom	of	inter-	menstrual	
bleeding
	Spontaneous	bleeding	occurring	between	
menstrual	periods
	Can	be	either	cyclical,	or	random
Abbreviations:	 FIGO,	 International	 Federation	 of	 Gynecology	 and	
Obstetrics;	HMB,	 heavy	menstrual	 bleeding;	NICE,	National	 Institute	 of	
Care	Excellence.
TABLE  2 Summary	of	changes	to	FIGO	AUB	System	2	Causes	or	
Contributors	to	AUB	in	the	Reproductive	Years	(PALM-	COEIN).
System 2 
category Change
AUB-	A Refined	sonographic	diagnostic	criteria
AUB-	L Inclusion	of	Type	3	as	a	submucous	leiomyoma
Type	definitions	and	distinctions
Distinction	between	Types	0	and	1;	6	and	7
Distinction	between	Types	2	and	3;	4	and	5
AUB-	C No	longer	includes	AUB	associated	with	pharmacologic	
agents	that	impair	blood	coagulation	which	are	now	
included	in	AUB-	I
AUB-	I Now	includes	AUB	associated	with	all	iatrogenic	
processes	including	the	use	of	pharmacological	agents	
used	for	anticoagulation	and	those	thought	to	interfere	
with	ovulation
AUB-	O Diagnostic	threshold	changes	based	upon	the	revisions	
of	System	1,	described	above
No	longer	includes	ovulatory	disorders	associated	with	
drugs	known	or	suspected	to	interfere	with	ovulation
AUB-	N The	name	of	the	category	has	been	changed	from	“Not	
Yet	Classified”	to	Not	Otherwise	Classified
There	is	a	brief	discussion	of	a	potential	new	cause	of	
AUB	the	so-	called	uterine	“niche”	or	isthmocele	
following	lower	segment	cesarean	section
Abbreviations:	 AUB,	 abnormal	 uterine	 bleeding;	 FIGO,	 International	
Federation	of	Gynecology	and	Obstetrics.
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the	mean	diameter	of	the	leiomyoma.	Types	0	and	7	now	comprise	leio-
myomas	that	have	a	stalk	diameter	that	is	10%	or	less	than	the	mean	
diameter	of	the	leiomyoma.	Hysteroscopy	has	now	been	deemed	the	
standard	for	distinguishing	between	a	Type	2	and	3	leiomyoma,	with	
the	determination	based	upon	the	lowest	filling	pressure	that	allows	
visualization	of	the	endometrial	cavity.	Distinguishing	between	Type	4	
and	Type	5	leiomyomas	should	be	based	upon	observation	of	distor-
tion	of	the	serosa	(Type	5)	as	determined	by	ultrasonography	or	MRI.
FIGO	now	provides	additional	guidance	for	investigators	using	the	
FIGO	subclassification	system	for	leiomyomas.	A	minimal	data	set	for	
describing	leiomyomas	should	include	an	estimate	of	total	uterine	vol-
ume	based	on	 imaging	 (transabdominal	or	 transvaginal	ultrasonogra-
phy	or	MRI),	as	well	as	an	estimate	of	the	number	of	leiomyomas	(1,	2,	
3,	4,	or	greater	 than	4).	 If	such	 imaging	 is	not	available,	such	as	may	
be	 the	case	 in	 low-	resource	countries,	 the	minimum	data	 set	 should	
include	an	estimate	of	uterine	size	on	clinical	examination	as	equivalent	
F IGURE  2 FIGO	AUB	System	2.	PALM-	COEIN	System	for	Classification	of	Causes	of	AUB	in	the	Reproductive	Years.	The	basic	system	
comprises	four	categories	that	are	defined	by	visually	objective	structural	criteria	(PALM:	Polyp;	Adenomyosis;	Leiomyoma;	and	Malignancy	
and	hyperplasia),	four	that	are	unrelated	to	structural	anomalies	(COEI:	Coagulopathy;	Ovulatory	dysfunction;	Endometrial	disorders;	Iatrogenic	
causes),	and	one	reserved	for	entities	categorized	as	“Not	otherwise	classified”.	The	leiomyoma	category	(L)	is	subdivided	into	patients	with	
at	least	one	submucous	myoma	(LSM)	and	those	with	myomas	that	do	not	impact	the	endometrial	cavity	(Lo).	Modified	with	permission.
67 
Abbreviations:	AUB,	abnormal	uterine	bleeding;	FIGO,	International	Federation	of	Gynecology	and	Obstetrics.
F IGURE  3 Adenomyosis	diagnostic	criteria.	Graphical	depictions	of	the	eight	TVUS	criteria	proposed	by	the	MUSA	group	are	presented.	
These	include	asymmetrical	myometrial	thickening	(A);	myometrial	cysts	(B);	hyperechoic	islands	(C);	fan	shaped	shadowing	(D);	echogenic	
subendometrial	lines	and	buds	(E);	translesional	vascularity	(F),	where	present;	irregular	junctional	zone	(G);	and	an	interrupted	junctional	zone	
(H).	Identification	and	evaluation	of	the	junctional	zone	may	best	be	accomplished	with	three-	dimensional	ultrasonography.	For	the	present	
at	least,	the	presence	of	two	or	more	of	these	criteria	are	highly	associated	with	a	diagnosis	of	adenomyosis.	Reproduced	with	permission.31 
Abbreviations:	MUSA,	Morphological	Uterus	Sonographic	Assessment;	TVUS,	transvaginal	ultrasonography.
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to	a	gravid	uterus	of	“X”	weeks.	When	transvaginal	ultrasonography	or	
MRI	are	available,	the	location	(anterior,	posterior,	left,	right,	or	center)	
and	the	estimated	volume	of	up	to	four	individual	leiomyomas	should	
be	recorded.	Additionally,	the	location	in	the	vertical	plane	should	be	
described;	upper	half,	 lower	half,	 or	both.	When	more	 than	 four	 are	
present,	the	volume	of	the	largest	 leiomyoma	should	be	recorded,	as	
a	minimum.	If	other	leiomyomas	are	judged	to	be	of	equal	or	greater	
relevance	for	clinical	decision	making	based	on	location,	the	volume	of	
these	lesions	should	be	recorded	as	well.	If	the	endometrium	is	visual-
ized,	then	the	relationship	between	the	documented	myomas	and	the	
endometrium	should	be	described	using	the	FIGO	classification	system.
Women	 with	 AUB	 and	 associated	 malignant	 or	 premalignant	
lesions	 of	 the	 uterus	 (e.g.	 endometrial	 carcinoma,	 leiomyosarcoma,	
and	atypical	endometrial	hyperplasia	sometimes,	referred	to	as	endo-
metrial	intraepithelial	neoplasia	or	EIN34,35),	are	categorized	as	having	
AUB-	M.	Their	categorization	 is	 further	defined	using	existent	WHO	
and	FIGO	classification	and	staging	systems.36,37
AUB	 associated	with	 the	 use	 of	 selected	 categories	 of	 systemic	
pharmacotherapy	or	intrauterine	systems	or	devices,	is	classified	as	“iat-
rogenic”.38	In	addition	to	gonadal	steroids	such	as	estrogens,	progestins,	
and	androgens,	and	agents	that	directly	affect	their	production	or	local	
function,	this	category	now	includes	nonsteroidal	pharmaceuticals	that	
contribute	to	ovulatory	disorders,	such	as	those	that	affect	dopamine	
metabolism,	 including	phenothiazines	and	tricyclic	antidepressants.	 In	
the	original	categorization,	women	with	AUB	associated	with	the	use	
of	anticoagulants	were	categorized	with	coagulopathies	(AUB-	C);	in	this	
revision,	 they	 are	 considered	 iatrogenic	 and	 classified	 as	AUB-	I.	This	
includes	 the	modern,	 non-	vitamin-	K	 antagonists	 such	 as	 rivaroxaban	
that	appears	to	have	a	greater	impact	on	the	volume	of	menstrual	bleed-
ing	than	the	traditional,	vitamin	K	antagonists,	typified	by	warfarin.39,40
Category	“N”,	“not	otherwise	classified”	was	created	in	the	original	
system	to	accommodate	entities	that	are	rarely	encountered	or	are	ill	
defined.	These	 include,	but	 are	not	 limited	 to,	 entities	 such	as	 arte-
riovenous	malformations	 (AVMs)41	 and	 the	 lower	 segment	 or	 upper	
F IGURE  4 FIGO	leiomyoma	subclassification	system.	System	2	classification	system	including	the	FIGO	leiomyoma	subclassification	system.	
The	system	that	includes	the	tertiary	classification	of	leiomyomas	categorizes	the	submucous	group	according	to	the	original	Wamsteker	et	al.	
system68	and	adds	categorizations	for	intramural,	subserosal,	and	transmural	lesions.	Intracavitary	lesions	are	attached	to	the	endometrium	
by	a	narrow	stalk	(≤10%	or	the	mean	of	three	diameters	of	the	leiomyoma)	and	are	classified	as	Type	0,	whereas	Types	1	and	2	require	a	
portion	of	the	lesion	to	be	intramural—with	Type	1	being	less	than	50%	of	the	mean	diameter	and	Type	2	at	least	50%.	Type	3	lesions	are	
totally	intramural	but	also	about	the	endometrium.	Type	3	are	formally	distinguished	from	Type	2	with	hysteroscopy	using	the	lowest	possible	
intrauterine	pressure	necessary	to	allow	visualization.	Type	4	lesions	are	intramural	leiomyomas	that	are	entirely	within	the	myometrium,	with	no	
extension	to	the	endometrial	surface	or	to	the	serosa.	Subserous	(Types	5,	6,	and	7)	leiomyomas	represent	the	mirror	image	of	the	submucous	
leiomyomas—with	Type	5	being	at	least	50%	intramural,	Type	6	being	less	than	50%	intramural,	and	Type	7	being	attached	to	the	serosa	by	a	
stalk	that	is	also	≤10%	or	the	mean	of	three	diameters	of	the	leiomyoma.	Classification	of	lesions	that	are	transmural	are	categorized	by	their	
relationship	to	both	the	endometrial	and	the	serosal	surfaces.	The	endometrial	relationship	is	noted	first,	with	the	serosal	relationship	second	
(e.g.	Type	2–5).	An	additional	category,	Type	8,	is	reserved	for	leiomyomas	that	do	not	relate	to	the	myometrium	at	all,	and	would	include	
cervical	lesions	(demonstrated),	those	that	exist	in	the	round	or	broad	ligaments	without	direct	attachment	to	the	uterus,	and	other	so-	called	
“parasitic”	lesions.	Modified	with	permission.67	Abbreviation:	FIGO,	International	Federation	of	Gynecology	and	Obstetrics.
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cervical	 niche	 or	 “isthmocele”	 frequently	 found	 in	 association	 with	
previous	 cesarean	 delivery	 and	 sometimes	 attributed	 to	 as	 a	 cause	
of	AUB.42,43
5  | NOTATION
After	the	patient	has	undergone	appropriate	investigation,	discussed	
below,	she	could	be	found	to	have	one	or	more	potential	causes	of,	
or	contributors	to,	the	AUB	symptoms.	Consequently,	the	system	has	
been	designed	to	enable	appropriate	multi-	category	notation.	While	
it	is	recognized	that	this	increased	level	of	complexity	will	be	of	most	
value	 to	 specialists	 and	 researchers,	 it	 should	 have	 utility	 for	 any	
healthcare	provider.
This	 approach	 has	 been	 designed	 following	 the	 example	 of	 the	
WHO	 TNM	 staging	 of	 malignant	 tumors,	 with	 each	 component	
addressed	 for	 all	women	 investigated	 for	AUB	 symptoms	 using	 the	
two	FIGO	AUB	Systems.	For	example,	if	an	individual	was	suspected	to	
have	a	disorder	of	ovulation,	a	type	2	leiomyoma,	and	no	other	anoma-
lies,	they	would	be	categorized	as	follows	in	the	context	of	a	complete	
evaluation:	AUB	P0	A0	L1(SM) M0	 -	C0	O1	E0	 I0	N0.	 It	was	 recognized	
that	in	clinical	practice	the	use	of	such	full	notation	might	be	consid-
ered	cumbersome,	so	an	option	for	abbreviation	has	been	developed.	
The	abbreviated	FIGO	description	of	the	patient	previously	described	
would	be	AUB-	LSM;	-	O.
FIGO	now	encourages	clinicians	and	investigators	to	consider	the	
use	of	a	matrix	for	the	evaluation	of	patients	with	AUB	in	the	repro-
ductive	years	(Fig.	5).	This	allows	for	the	identification	and	documen-
tation	of	the	status	of	the	investigation.
6  | RECOMMENDATIONS FOR 
CLINICAL INVESTIGATION
A	woman	presenting	with	AUB	may	have	one	or	a	number	of	 fac-
tors	that	may	contribute	to	the	genesis	of	the	symptoms.	Using	FIGO	
AUB	System	1	 to	 define	 the	 types	 of	AUB	 symptoms	present	 is	 a	
prerequisite	to	evaluation	for	the	elements	in	FIGO	AUB	System	2.	
A	number	of	pathological	entities	(e.g.	subserous	leiomyoma)	may	be	
present	that	are	possibly	or	even	unlikely	to	be	a	contributor	to	the	
symptoms.	Consequently,	the	investigation	of	women	with	AUB	dur-
ing	the	reproductive	years	must	be	undertaken	in	as	comprehensive	
but	practicable	fashion	given	the	clinical	situation	and	the	available	
resources,	with	the	findings	carefully	interpreted	for	their	role	in	the	
symptoms.	For	example,	available	evidence	would	suggest	that	a	sin-
gle	 1-	cm	 polyp	would	 not	 be	 the	 cause	 of	 the	 symptom	 of	HMB.	
F IGURE  5 FIGO	AUB	System	2	diagnostic	matrix.	A	simplified	diagnostic	matrix	is	illustrated	in	the	left	pane.	Each	of	the	primary	
classification	system	elements	are	listed.	If	a	patient	has	not	been	completely	evaluated	for	a	potential	cause	it	is	listed	in	the	“?”	column,	if	
evaluation	has	demonstrated	no	evidence	of	the	abnormality	the	“N”	column	is	checked,	and	if	assessment	is	positive,	an	X	is	placed	in	the	
appropriate	box.	An	example	is	shown	in	the	panel	on	the	right.	The	patient	has	the	symptom	of	HMB,	and	interim	assessment,	including	
contrast	hysterosonography	documented	in	the	left	matrix	has	revealed	a	subserosal	leiomyoma	designated	as	Lo.	However,	the	patient	
had	a	positive	historical	screening	result	for	coagulopathy	and	hematological	assessments	for	coagulation	disorders	are	not	yet	available.	
Consequently,	the	“C”	and	“E”	rows	remain	in	the	“?”	category.	The	hematological	assessment	demonstrates	that	there	is	no	evidence	of	
coagulopathy,	so	the	diagnosis	of	a	primary	disorder	of	endometrial	hemostasis	is	made.	The	C	row	can	now	be	assigned	an	“N”	while	the	E	
category	can	be	checked	as	“Y”.	Abbreviations:	AUB,	abnormal	uterine	bleeding;	FIGO,	International	Federation	of	Gynecology	and	Obstetrics;	
HMB,	heavy	menstrual	bleeding.
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A	suggested	approach	is	illustrated	in	Figure	6A,B,	and	described	in	
brief	below.
6.1 | General assessment
When	 evaluating	 a	woman	 of	 reproductive	 age	with	 either	 acute	
or	 chronic	 genital	 tract	 bleeding	 thought	 to	be	AUB,	 the	 clinician	
should	 ensure	 that	 the	 bleeding	 is	 not	 related	 to	 pregnancy,	 and	
is	emanating	 from	the	cervical	canal,	 rather	 than	another	 location	
such	as	the	vagina,	vulva,	perineum,	or	perianal	region.	Pregnancy	
may	be	reliably	confirmed	with	a	urine	or	serum	assay	for	the	pres-
ence	 of	 the	 β-	subunit	 of	 human	 chorionic	 gonadotropin	 (hCG).	 It	
is	 to	 be	noted	 that	 determination	of	 the	 location	or	 viability	 of	 a	
pregnancy	is	not	considered	to	be	within	the	domain	of	the	FIGO-	
AUB	systems.	Women	with	both	acute	and	chronic	AUB	should	be	
evaluated	for	iron	deficiency,	if	possible,	with	serum	ferritin,	and	for	
related	anemia	by	measuring	hemoglobin	and/or	hematocrit	(pref-
erably	a	full	blood	count,	including	platelets).	Once	the	bleeding	has	
been	confirmed,	or	suspected,	to	originate	 in	the	cervical	canal	or	
endometrial	cavity,	the	clinician	should	systematically	evaluate	the	
patient	 for	 each	 of	 the	 components	 of	 FIGO	AUB	 System	 2,	 the	
PALM-	COEIN	classification.
6.2 | Determination of ovulatory status
Predictable	 cyclic	 menses	 every	 24–38	days	 are	 usually	 (but	 not	
always)	associated	with	ovulation	whereas	bleeding	associated	with	
ovulatory	disorders	is	typically	irregular	in	timing	and	flow,	and	often	
interspersed	with	episodes	of	amenorrhea.
If,	 largely	 based	 on	 FIGO	AUB	 System	 1,	 a	woman	 is	 found	 to	
have	AUB	related	to	a	ovulatory	disorder,	she	is	to	be	categorized	as	
AUB-	O.	 If	 there	 is	 uncertainty	 regarding	 ovulatory	 status,	measure-
ment	of	serum	progesterone,	timed	to	the	best	estimate	of	mid-	luteal	
phase,	may	 be	 useful	 for	 confirming	 ovulation	 in	 the	 current	 cycle.	
Whereas	 endometrial	 biopsy	 is	 not	 recommended	 as	 a	method	 for	
determination	of	ovulatory	status,	when	performed	and	appropriately	
indicated—to	evaluate	for	the	presence	of	premalignant	or	malignant	
endometrial	 change—histopathological	 findings	 reflecting	 secretory	
change	may	confirm	that	ovulation	has	occurred.
6.3 | Screening for systemic disorders of hemostasis
A	 structured	history	 is	 a	 useful	 and	effective	 screening	 tool.	 FIGO	
suggests	a	 tool	 that	has	been	demonstrated	 to	have	90%	sensitiv-
ity	 for	 the	detection	of	 these	 relatively	 common	disorders	 (coagu-
lopathies)44	 (Table	3).	 For	 those	 with	 a	 positive	 screening	 result,	
further	 testing	 is	 necessary,	 often	 following	 consultation	 with	 a	
physician	with	a	special	interest	in	disorders	of	coagulation,	such	as	
a	 hematologist.	 Such	 tests	may	 include	 assays	 for	 von	Willebrand	
factor,	 Ristocetin	 cofactor,	 partial	 thromboplastin	 time	 (PTT)	 and	
other	measures.45	 If	 the	 results	are	positive,	 the	woman	with	AUB	
would	be	being	categorized	as	having	AUB-	C.	Previously,	by	conven-
tion,	 individuals	with	AUB	associated	with	the	use	of	anticoagulant	
therapy	were	categorized	as	AUB-	C,	but	they	now	are	included	in	the	
AUB-	I	category.
6.4 | Evaluation of the endometrium
Endometrial	 sampling	 is	not	 required	 for	 all	 patients	with	AUB,	 so	
it	is	necessary	to	identify	the	women	for	whom	endometrial	biopsy	
is	 appropriate.	 Selection	 for	 endometrial	 sampling	 is	 based	 on	
a	 combination	 of	 risk	 factors	 for	 the	 presence	 of	 premalignant	 or	
malignant	changes,	comprising	some	combination	of	age,	personal,	
and	genetic	risk	factors,	and	TVUS	screening	for	endometrial	echo-	
complex	thickness.5,46–49	Although	some	studies	have	indicated	that	
age	is	not	important	as	an	independent	variable,47	most	suggest	that	
endometrial	 sampling	 be	 considered	 for	 all	 women	 over	 a	 certain	
age,	usually	45	years.5	It	is	also	evident	that	obesity	contributes	sig-
nificantly	 to	 the	 risk	 of	 premalignant	 and	malignant	 change	 in	 the	
endometrium,	a	feature	that	increases	the	risk	of	endometrial	neo-
plasia	even	in	young	women	in	the	third	and	fourth	decades	of	life.50 
Women	with	a	family	history	of	hereditary	nonpolyposis	colorectal	
cancer	syndrome,	now	called	Lynch	Syndrome,	have	a	lifetime	risk	of	
endometrial	cancer	of	up	to	60%,	with	the	mean	age	at	diagnosis	of	
48–50	years.51,52	Regardless	of	 the	clinical	guideline,	when	AUB	 is	
persistent	and	either	unexplained	or	inadequately	treated,	endome-
trial	sampling	is	necessary—if	possible—in	association	with	hystero-
scopic	evaluation	of	the	uterine	cavity.28	Sonohysterography	is	likely	
a	reasonable	substitute	for	hysterography	to	diagnose	for	polyps	and	
submucous	leiomyomas.53–55	There	exist	a	number	of	techniques	for	
endometrial	 sampling,	but	 it	 is	 important	 that	 an	adequate	 sample	
be	obtained	before	the	patient	can	be	considered	at	 low	risk	for	a	
malignant	neoplasm.56
It	is	apparent	that	a	relationship	exists	between	chlamydial	infec-
tion	of	the	endometrium	and	AUB.	Consequently,	it	may	be	prudent	to	
consider	evaluating	for	the	presence	of	the	organism	in	symptomatic	
patients.57	Although	cervical	assays	seem	reasonable,	the	relationship	
between	cervically	obtained	specimens	and	the	presence	of	absence	
of	endometrial	infection	is	unclear.58	If	chronic	endometritis	is	identi-
fied,	patients	should	be	categorized	as	having	AUB-	E.
6.5 | Evaluation of the structure of the 
endometrial cavity
Evaluation	 for	 structural	 abnormalities	 affecting	 the	 endometrial	
cavity	 is	 performed	 to	 identify	 pathology—including	 endometrial	 or	
endocervical	polyps	and	submucous	leiomyomas—that	could	contrib-
ute	to	AUB.	Transvaginal	ultrasonography	(TVUS)	is	an	appropriate	and	
important	screening	tool	and,	in	most	instances,	should	be	performed	
early	 in	the	course	of	the	 investigation.	 Ideally,	the	ultrasonography	
system	must	be	of	adequate	quality	to	clearly	display	both	myometrial	
and	endometrial	 features,	 and	 the	examiner	 should	have	 the	ability	
to	 operate	 the	 scanning	 device	 and	 interpret	 the	 images	 displayed.	
Regardless,	TVUS	is	not	100%	sensitive	even	in	 ideal	circumstances	
because	polyps	and	other	small	lesions	may	elude	detection,	even	in	
the	context	of	a	normal	study.59,60
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(A)
(B)
FIGURE 6 Investigative	algorithms	for	patients	with	chronic	AUB	during	the	reproductive	years.	(A)	Initial	investigation	comprises	a	structured	
history,	physical	examination,	and	the	use	of	appropriate	ancillary	investigations,	in	part	based	upon	the	history	and	physical	assessment.	
Evidence	suggesting	an	ovulatory	disorder	prompts	assessment	for	endocrinopathy,	whereas	a	positive	screening	result	for	coagulopathy	
(Figure	7)	will	indicate	the	need	for	appropriate	hematological	assessment.	A	complete	blood	count	should	be	performed	on	all	women	with	
the	symptom	of	heavy	menstrual	bleeding.	(B)	A	pragmatic	guide	to	uterine	assessment.	If	the	initial	evaluation	(Figure	6A)	suggests	a	low	
risk	for	coagulopathy,	structural	or	malignant/premalignant	change,	patients	may	be	presumed	to	have	AUB-	E	or	-	O	and	offered	appropriate	
treatment	options.	However,	if	there	is	an	enhanced	risk	for	endometrial	hyperplasia	or	malignancy	(left),	endometrial	sampling	is	recommended.	
If	an	adequate	specimen	is	not	obtained,	hysteroscopic	examination	and	biopsy	is	recommended.	If	there	is	an	enhanced	risk	for	a	structural	
abnormality,	transvaginal	ultrasonography	is	the	next	step	(right).	If	evaluation	of	the	endometrium	is	suboptimal	or	there	is	a	suggestion	of	an	
abnormality	affecting	the	endometrial	cavity,	either	hysteroscopy	or	contrast	hysterosonography	is	indicated.	MRI	may	be	occasionally	indicated	
if	hysteroscopy	or	contrast	hysterosonography	are	not	feasible,	such	as	in	the	case	of	virginal	women.	Abbreviations:	AUB,	abnormal	uterine	
bleeding;	MRI,	magnetic	resonance	imaging;	TVUS,	transvaginal	ultrasonography.	Images	are	used	courtesy	of	Malcolm	G.	Munro.
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If	 good	 ultrasonic	 images	 fail	 to	 show	 findings	 suggestive	 of	
endometrial	polyps	or	submucous	leiomyomas,	the	clinician	may	ini-
tially	presume	that	the	structure	of	the	endometrial	cavity	is	normal.	
However,	 if	there	are	imaging	features	that	 indicate	the	presence	of	
endometrial	polyp(s),	 if	 there	are	 leiomyomas	 that	may	encroach	on	
the	 endometrial	 cavity,	 or	 if	 the	 examination	 is	 suboptimal,	 imag-
ing	 with	 more	 sensitive	 techniques	 is	 recommended.	 These	 gener-
ally	 include	 hysteroscopy	 and/or	 transvaginal	 ultrasonography	 with	
intrauterine	contrast,	either	gel	or	saline,	termed	sonohysterography.	
Which	of	these	techniques	is	used	will	depend	on	the	resources	avail-
able	to	the	clinician.53–55	In	most	instances,	sonohysterography	will	be	
more	readily	available,	particularly	when	the	only	available	resources	
for	hysteroscopy	reside	in	an	operating	room.	However,	if	office	hys-
teroscopy	is	available,	there	may	be	additional	value,	particularly	when	
polyps	are	suspected,	as	hysteroscopically	directed	polypectomy	will	
be	feasible	in	the	same	setting.
In	 some	 parts	 of	 the	world,	 notably	 in	 the	UK	 (managed	 by	 the	
British	National	Health	Service),	 there	 is	 an	emphasis	on	conducting	
investigation	 and	management	 of	 the	 symptom	 of	HMB	 at	 the	 first	
consultation	(“One	stop	management”,	including	key	history,	examina-
tion,	 transvaginal	 ultrasonography,	 and	 hysteroscopy,	 if	 indicated,	 at	
the	same	visit).28	This	 type	of	management	has	been	assisted	by	the	
systematic	application	of	the	two	FIGO	AUB	Systems	–	clearly	defining	
the	symptoms	using	FIGO	AUB	System	1,	and	then,	following	an	appro-
priately	structured	evaluation,	categorization	of	the	findings	or	assess-
ments	using	FIGO	AUB	System	2,	the	PALM-	COEIN	classification.
When	vaginal	access	is	difficult	or	impossible,	a	circumstance	often	
encountered	 with	 adolescents	 and	 virginal	 women,	 TVUS,	 contrast	
sonohysterography,	 and	office	hysteroscopy	may	not	 be	 feasible.	 In	
such	 instances,	 there	 is	 a	 role	 for	MRI.	Alternatively,	 hysteroscopic	
examination	 with	 indicated	 biopsies,	 performed	 under	 appropriate	
anesthesia	may	be	the	best	approach.
With	 the	PALM-	COEIN	classification,	 the	presence	of	a	polyp	or	
polyps	(AUB-	P)	is	confirmed	only	with	documentation	of	one	or	more	
clearly	defined	polyps,	generally	with	either	hysteroscopy	or	sonohys-
terography.	Usually,	 a	 patient	may	 be	 categorized	with	 one	 or	more	
submucous	 leiomyomas	 (AUB-	LSM)	 with	 either	 sonohysterography	
or	hysteroscopy.	When	using	either,	 the	clinician	should	take	care	to	
infuse	 the	 distending	medium	with	 low	 pressure	 so	 that	 the	 natural	
relationships	 of	 the	 leiomyoma	with	 the	 endometrium	 and	 myome-
trium	are	distorted.	As	described	above,	FIGO	now	recommends	that	
the	distinction	between	Type	2	and	3	leiomyomas	be	based	upon	hys-
teroscopy	performed	using	the	lowest	pressure	necessary	to	evaluate	
these	relationships.	The	use	of	sonohysterography	for	this	purpose	is	
considered	to	be	a	suitable	and	more	practical	substitute	in	a	variety	
of	clinical	situations.
6.6 | Myometrial assessment
For	the	primary	leiomyoma	categorization,	the	myometrium	is	assessed	
primarily	with	a	combination	of	TVUS	and	transabdominal	ultrasonog-
raphy	to	identify	leiomyomas,	with	any	such	identified	lesion	leading	
to	an	“L”	assignment.	For	the	secondary	subclassification,	it	is	neces-
sary	to	determine	the	relationship	(contact	or	not)	of	the	endometrium	
with	the	leiomyoma	by	performing	some	combination	of	TVUS,	con-
trast	sonohysterography,	hysteroscopy,	and	MRI.	Should	one	or	more	
submucous	leiomyomas	be	found	(Types	0,	1,	2,	or	3)	then	the	woman	
is	stated	to	have	LSM,	if	only	Type	4,	5,	6,	7,	and/or	8	are	identified,	the	
categorization	is	Lo.
Tertiary	subclassification	of	leiomyoma	type	requires	that	the	clini-
cian	clarify	the	relationship	of	the	leiomyomas	with	the	endometrium,	
endometrial	cavity,	myometrium,	and	uterine	serosa.	At	least	for	those	
leiomyomas	that	do	not	distort	 the	endometrial	cavity	 (Types	3	and	
up),	this	distinction	requires	the	use	of	 imaging,	either	ultrasonogra-
phy,	or,	more	accurately	MRI	as	described	previously.
The	 myometrium	 should	 also	 be	 evaluated	 for	 the	 presence	 of	
adenomyosis	or	to	distinguish	between	leiomyomas	and	localized	col-
lections	of	adenomyosis	or	adenomyomas.31,61	The	sonographic	and	
MRI	criteria	for	the	diagnosis	of	adenomyosis	are	described	elsewhere	
in	the	present	document.	While	the	FIGO	MDC	is	currently	develop-
ing	a	system	for	the	classification	of	adenomyosis,	for	the	present,	an	
assignment	 of	AUB-	A	 is	 best	 based	 on	 imaging	 findings	 consistent	
with	TVUS	as	described	above31	 (Fig.	3)	or,	 if	available,	using	MRI.30 
Although	promising	for	the	diagnosis	of	adenomyosis,	the	role	of	both	
three-	dimensional	TVUS62,63	and	sonographic	elastography64,65	is	still	
a	subject	of	investigation.
If	 available,	 MRI	 may	 be	 necessary	 for	 evaluation	 of	 the	 myo-
metrium	 to	distinguish	between	 leiomyomas	and	adenomyosis.	MRI	
FIGURE  7 Four	examples	of	the	use	of	a	matrix	to	guide	FIGO-	based	evaluation	of	patients	with	chronic	AUB.	(A)	Patient	with	the	symptom	
of	heavy	menstrual	bleeding	(duration	of	menses	10	d	and	perceived	and	affecting	the	patient’s	quality	of	life).	Contrast	sonohysterography	
demonstrates	a	posterior	Type	2	leiomyoma	1.85	by	1.49	cm	in	diameter.	All	other	investigations	have	been	completed	and	are	negative.	Diagnosis:	
AUB-	LSM.	(B)	Here	the	cycle	length	varies	from	14	to	60	d,	the	duration	of	menstrual	bleeding	from	2	to	11	d,	and	the	volume	ranging	from	light	
to	heavy.	Transvaginal	sonography	shows	a	posterior	Type	6	leiomyoma.	Other	investigations	are	normal	save	the	thyroid-	stimulating	hormone,	
which	is	elevated.	Diagnosis:	AUB-	Lo;	-	O	with	the	primary	cause	of	AUB	the	ovulatory	disorder	secondary	to	hypothyroidism.	(C)	In	this	example	the	
patient’s	menstrual	parameters	are	normal	with	the	exception	of	her	complaint	of	intermittent	intermenstrual	bleeding.	Contrast	sonohysterography	
shows	an	endometrial	polyp	and	a	Type	5	leiomyoma	(not	shown).	The	hysteroscopic	view	at	the	time	of	the	polypectomy	is	shown.	Diagnosis:	
AUB-	P;	-	Lo	with	the	primary	cause	of	the	AUB	the	endometrial	polyp.	(D)	This	patient	has	the	complaint	of	lifelong	heavy	menstrual	bleeding	that	
is	becoming	heavier,	with	clots,	and	associated	with	worsening	dysmenorrhea	that	lasts	the	entire	period.	She	has	a	history	of	easy	bruising	and	
frequently	bleeds	when	brushing	her	teeth.	Her	menses	are	cyclically	predictable	with	a	normal	cycle	length	of	33	d.	Transvaginal	ultrasonography	
shows	a	globular	uterus,	an	asymmetrically	thickened	posterior	myometrium,	and	fan-	shaped	shadowing.	All	of	the	coagulation	parameters	
measured	were	abnormal,	and	consistent	with	vWD	Type	1.	Diagnosis:	AUB-	A,	-	C.	Abbreviations:	AUB,	abnormal	uterine	bleeding;	FIGO,	
International	Federation	of	Gynecology	and	Obstetrics;	vWD,	von	Willebrand	disease.	Images	are	used	courtesy	of	Malcolm	G.	Munro.
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imaging	may	also	be	superior	to	TVUS,	sonohysterography,	and	hys-
teroscopy	for	measuring	the	myometrial	extent	of	submucous	leiomy-
omas.59	However,	reliance	on	MRI	is	currently	impractical,	especially	
for	 low-	resource	nations,	because	of	the	relative	or	absolute	 lack	of	
access	within	many	healthcare	systems.66
7  | DISCUSSION
AUB	in	women	of	reproductive	age	is	a	manifestation	of	any	of	a	number	
of	disorders	or	pathologic	entities.	The	FIGO	systems	for	nomenclature	
and	symptoms	(System	1),	and	for	classification	of	potential	causes	of	
AUB	in	the	reproductive	years	(System	2)	are	designed	to	facilitate	both	
basic	science	and	clinical	investigation,	as	well	as	the	practical,	rational,	
and	consistent	application	of	medical	and	surgical	therapy	for	affected	
women.	 The	 current	 revisions	 of	 the	 two	 FIGO-	AUB	 systems	 are	
designed	to	clarify	and	modify,	in	a	fashion	that	should	improve	the	util-
ity	of	these	systems	for	research,	education,	and	clinical	care.	Clinicians,	
educators,	and	investigators	are	encouraged	to	use	the	matrix	concept	
to	guide	the	evaluation	of	women	afflicted	with	chronic	AUB,	as	well	as	
acute	AUB	once	the	patient	is	stabilized	(Fig.	7).
These	systems,	and	their	continued	and	appropriate	revision,	repre-
sent	a	collaboration	involving	clinicians,	investigators,	and	other	informed	
participants	 from	 six	 continents.	 This	 participation	 was	 designed	 to	
develop	an	implementable	System	1	and	to	provide	input	into	the	practi-
cality	of	performing	the	investigations	described	for	categorizing	accord-
ing	to	System	2,	the	PALM-	COEIN	classification.	Currently,	the	routine	
characterization	of	structural	lesions	of	the	uterus	using	MRI	is	not	feasi-
ble	and	its	use	is	not	included	as	a	mandatory	tool	for	evaluating	patients	
with	chronic	AUB.	This	does	not	mean	that	clinicians	cannot	or	should	
not	use	MRI	if	 it	 is	deemed	necessary	and	is	available,	with	the	results	
used	to	categorize	leiomyoma	type	or	determine	the	presence,	absence,	
or	location	and	extent	of	adenomyosis.
8  | CONCLUSION
The	present	paper	reports	the	changes	to	both	FIGO	AUB	systems	
based	 on	 6	years	 of	 analysis,	 discussion,	 and	 debate	 since	 the	
original	 publication.	 The	 original	 seminal	 publications	 presented	
effective	approaches	to	the	terminologies	and	definitions	around	
AUB	(System	1),	followed	by	development	of	a	novel	classification	
(PALM-	COEIN)	 of	 underlying	 causes	 of	 abnormal	 uterine	 bleed-
ing	 in	 the	 reproductive	 years	 (System	2).14	 These	 developments	
and	refinements	are	 integrated	 into	the	whole	FIGO-	AUB	model	
in	this	manuscript.
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with excessive menstrual bleeding should be by a structured history. 
A positive screening result comprises any of the following:c
1.	Heavy	menstrual	bleeding	since	menarche
2.	One	of	the	following:
a	Postpartum	hemorrhage
b	Surgical	related	bleeding
c	Bleeding	associated	with	dental	work
3.	Two	or	more	of	the	following	symptoms:
a	Bruising	1–2	times	per	month
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d	Family	history	of	bleeding	symptoms
aReproduced	with	permission.45
bThis	 structured	history-	based	 instrument	 is	90%	sensitive	 for	 the	pres-
ence	of	a	coagulopathy	in	women	with	the	symptom	of	heavy	menstrual	
bleeding.
cPatients	with	a	positive	screening	result	should	be	considered	for	further	
evaluation	 including	 consultation	with	 a	 hematologist	 and/or	 testing	 of	
von	Willebrand	factor	and	Ristocetin	cofactor.
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